3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
5
Terminated
3
Completed
3
Withdrawn
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
3
Stomach Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Peritoneal Neoplasms
1
Ovarian Epithelial Cancer Recurrent
1
Neoplasm Metastasis
1
HIPEC
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Appendiceal Neoplasms
1
Interventions
Paclitaxel
17
Carboplatin
16
Magnetic Resonance Spectroscopy
11
Taxes
10
Specimen Handling
10
Bevacizumab
10
olaparib
9
Gemcitabine
9
pembrolizumab
8
Immunoglobulin G
7
Disulfides
7
Biopsy
7
liposomal doxorubicin
6
Doxorubicin
5
cediranib
4
Nivolumab
4
Cyclophosphamide
4
Cisplatin
4
oregovomab
3
niraparib
3
adavosertib
3
X-Rays
3
Topotecan
3
tremelimumab
2
rucaparib
2
mirvetuximab soravtansine
2
berzosertib
2
aldesleukin
2
Surveys and Questionnaires
2
Platinum
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Fallopian Tube Neoplasms
×
Hyperthermic Intraperitoneal Chemotherapy
×
Clear all
NCT02124421
2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2
Active not recruiting
32 enrolled